Twelve Seas Investment Company III is a shell company that completed its IPO on December 15, 2025, raising $172.5 million held in trust. As of September 30, 2026, the company has 17,745,000 Class A and 5,692,500 Class B ordinary shares outstanding and is seeking a business combination within a 24-month window ending December 15, 2027.
Beyond Air reported record quarterly revenue of $2.3 million for the period ended September 30, 2026, representing 28% year-over-year growth. The company reaffirmed its revenue guidance of $8 million for CY2026 and $16-$18 million for CY2027 while awaiting FDA approval for its second-generation LungFit PH system.
Term
Q2 2027
“Building on the commercial momentum we are generating with our first-generation LungFit PH system, we believe our second-generation system has the potential to substantially expand our market opportunity and accelerate growth, pending FDA approval.”
Robert Goodman, Chief Executive Officer of Beyond Air
“We remain encouraged by our active and productive discussions with the FDA and the progress we are making toward completing the remaining steps in the review process for the second-generation LungFit PH system.”
Robert Goodman, Chief Executive Officer of Beyond Air
Spruce Power Holding Corp reported 19,294,133 shares of common stock outstanding as of November 9, 2026. The company's cash and cash equivalents decreased from $54.8 million at the end of 2025 to $40.1 million as of September 30, 2026, while management highlighted risks related to debt refinancing and solar industry demand.
Evofem Biosciences reported Q3 2026 financial results, achieving $0.7 million in operating income despite a slight decline in net sales to $4.6 million. The company highlighted the shipment of its 500,000th box of PHEXX and the addition of a fifth study site for an NIH-funded Phase 4 trial of SOLOSEC.
Term
Q3 2026
“While third quarter net sales reflect the cumulative impact of operating without dedicated growth capital for brand promotion and physician outreach since late 2022, we are proud of the discipline, efficiency and tenacity demonstrated across the organization. Through rigorous expense management, we generated $0.7 million of operating income during the quarter while continuing to support patients and healthcare providers who rely on our innovative sexual health products.”
BioScience Health Innovations, Inc. reported a net loss of $564,885 for the nine months ended September 30, 2026, a significant decline from the $875,720 net income in the prior year period. Despite the loss, the company successfully raised over $2 million through common stock sales, ending the period with a strengthened cash position of $1,691,858.
KKR Private Equity Conglomerate LLC reported a net increase in net assets resulting from operations of $975.5 million for the nine months ended September 30, 2026, compared to $762.1 million in the prior year period. Total assets grew to $13.6 billion, driven by a significant increase in investments at fair value and cash holdings.
Evofem Biosciences reported a significant decline in total assets from $20.3 million at year-end 2025 to $7.3 million as of September 30, 2026, driven largely by a decrease in trade accounts receivable and intangible assets. The company faces substantial liquidity challenges with $84.8 million in current liabilities and has received notices of default from Future Pak, LLC regarding its debt obligations.
Senior Credit Investments, LLC reported a net increase in member’s capital resulting from operations of $18.4 million for the nine months ended September 30, 2026, up from $12.0 million in the prior year period. Total investment income grew significantly to $40.4 million, driven by interest income from its non-controlled/non-affiliated investment portfolio, while net asset value per unit decreased slightly to $1,767.94 from $1,787.98 at year-end 2025.
Jefferies Credit Partners BDC Inc. reported a net increase in net assets resulting from operations of $52.0 million for the nine months ended September 30, 2026, compared to $30.5 million for the same period in 2025. Total net assets grew to $964.9 million from $677.0 million at year-end 2025, driven by significant capital share issuances and investment income growth.
The 21Shares Solana Staking ETF reported net assets of $9,786,070 as of September 30, 2026, a significant increase from $5,735,019 at the end of 2025. The Trust generated $102,143 in staking rewards for the nine months ended September 30, 2026, and transitioned its pricing benchmark to the FTSE Solana Index in August 2026.
Blue Line Holdings, Inc. remains a pre-revenue industrial company with a net loss of $12,459 for the quarter ended September 30, 2026. The company reported a working capital deficit of $90,521 and expressed substantial doubt regarding its ability to continue as a going concern without additional financing.
For the quarter ended September 30, 2026, INVE Technologies reported a net income of $0.6 million, a significant improvement from a $3.5 million loss in the prior year, primarily driven by a $6.1 million gain on an asset sale. However, total revenue decreased to $3.1 million from $5.0 million year-over-year, and the company recorded a nine-month net loss of $7.5 million.
Femasys Inc. reported a decrease in sales for the nine months ended September 30, 2026, totaling $1,161,313 compared to $1,479,926 in the prior year period. The company significantly strengthened its balance sheet, ending the quarter with $23.9 million in cash and cash equivalents following financing activities, while maintaining an accumulated deficit of $154 million.
Edgemode, Inc. reported a net loss of $10.5 million for the nine months ended September 30, 2026, compared to a loss of $14.4 million in the prior year period. The company's balance sheet shows a significant stockholders' deficit of $7.6 million and a substantial reduction in derivative liabilities from $15.4 million to $1.5 million during the year.
American Strategic Investment Co. reported a net loss of $22.8 million for the nine months ended September 30, 2026, compared to a $14.5 million loss in the prior year. The company's total equity decreased to $47.3 million from $64.8 million at year-end 2025, primarily driven by the net loss and offset by common stock issuances to its Advisor.
This document is a formal consent from Altus Group U.S., Inc. allowing Hines Global Income Trust, Inc. to reference their role as an independent valuer in the company's Q3 2026 Quarterly Report. It specifically pertains to the valuation process described in the Net Asset Value section of the filing.
Origin Investment Corp I reported a net income of $1,165,890 for the nine months ended September 30, 2026, primarily driven by $1,937,643 in interest income from its Trust Account. As a blank check company, it has not yet commenced operations or generated revenue, and its total assets of $73.36 million are largely comprised of investments held in trust for a future business combination.
Cerenome (formerly Plus Therapeutics) reported Q3 2026 financial results, highlighting its first quarter of CNSide diagnostic revenue totaling $0.7 million. The company expanded its payer coverage to approximately 190 million lives and completed enrollment in its Phase 2 glioblastoma trial. Additionally, the company rebranded from Plus Therapeutics to Cerenome during the quarter.
Term
Q3 2026
“Recognition of our first quarter of CNSide® diagnostic revenue and commercial payments beginning in October is a tremendous landmark. Furthermore, our payer universe continues to expand with now about 80% of U.S. private payers representing approximately 190 million covered lives. Most recently, with Aetna coverage, it gives physicians an in-network option for both tumor cell enumeration and molecular profiling. In parallel, our growing commercial team is focused on helping more cancer centers use our test in patient care. In therapeutics, we materially advanced our two key programs by completing enrollment in our Phase 2 trial in adults with recurrent glioblastoma, opening up higher dose cohorts in the repeat dosing of REYOBIQ™ in patients with leptomeningeal metastases and reporting interim data in that trial.”
Marc H. Hedrick, M.D., Cerenome’s President and Chief Executive Officer
CKX Lands, Inc. reported net income of $621,499 for the nine months ended September 30, 2026, an increase from $442,919 in the prior year period, driven largely by higher surface revenue and interest income. Total assets remained stable at approximately $22.4 million, while the company maintained a strong liquidity position with $15.9 million in cash and cash equivalents.
Seritage Growth Properties reported Q3 2026 financial results, achieving net income of $2.7 million compared to a net loss for the nine-month period. The company generated $3.0 million from asset sales and received an $8.9 million distribution from an unconsolidated entity, while continuing to evaluate strategic options for its remaining portfolio.
Term
Q3 2026
“Although we have no new transactions under contract, we continue to work on both individual asset sales and potential strategic options for the portfolio and the Company”
Grown Rogue International Inc. reported total revenue of $31.45 million for the nine months ended September 30, 2026, compared to $23.67 million in the prior year period. The company experienced a net loss of $12.58 million for the nine-month period, primarily driven by a $5.03 million loss on the acquisition of Rogue EBC and significant increases in general and administrative expenses.
American Strategic Investment Co. reported third quarter 2026 revenue of $7.1 million and a net loss of $6.7 million. The results reflect a decrease in revenue compared to the prior year due to the disposition of the 1140 Avenue of the Americas property. Subsequent to the quarter, the company signed a major lease extension and expansion with the State of New York at its 123 William Street property.
“The Company’s results this quarter build on the progress we made over the last two quarters, as our capital prioritization strategy continues to contribute to our results. The portfolio’s high quality, largely investment grade tenant base continues to support stable performance this year.”
Nicholas Schorsch, Jr., CEO of ASIC
“We remain focused on completing our remaining asset dispositions and directing capital toward the opportunities we believe will create the most durable value for our shareholders, such as the execution of the lease with the State of New York after the end of the quarter that increases pro-forma occupancy at 123 William Street to approximately 75% and portfolio occupancy to approximately 78%.”
Femasys reported financial results for the third quarter of 2026, highlighting a slight increase in U.S. sales to $0.35 million despite overall sales declining due to international distributor order timing. The company completed a $30 million private placement in August to fund the build-out of its U.S. commercial team and support the FemBloc pivotal trial.
Term
Q3 2026
“We maintained a lean team and tightly managed resources as we prioritized financing from long-term institutional investors. Closing the $30 million in financing in mid-August 2026 represents an important turning point for Femasys.”
Kathy Lee-Sepsick, Founder and Chief Executive Officer
“These results and commercial recruitment progress give us strong confidence that deploying our team in target U.S. territories will broaden adoption and drive revenue growth.”
Kathy Lee-Sepsick, Founder and Chief Executive Officer
For the nine months ended September 30, 2026, AB Private Credit Investors Corp reported net investment income after tax of $47.9 million, a significant increase from $42.3 million in the prior year period. However, net assets resulting from operations decreased to $24.2 million from $41.7 million year-over-year, primarily due to $22.3 million in net unrealized depreciation on investments.
NextPlat Corp reported third quarter 2026 financial results featuring a 35% improvement in gross profit and a 66% reduction in net loss. While consolidated revenue decreased to $10.5 million due to lower reimbursement rates, the company saw 300% growth in high-margin pharmacy contract revenue, specifically driven by 340B services.
Term
Q3 2026
“Our third quarter results reflect continued year-over-year improvement across the business, driven by the refocusing of our healthcare operations on high-value, high-margin services designed to deliver consistent bottom-line results in what remains a dynamic market.”
David Phipps, Chief Executive Officer and President of NextPlat Corp
“Our focus remains on growth and profitability through our differentiated, high-value healthcare services and expanding community pharmacy network, including our new Scott’s location near Pensacola and a new pharmacy in Jacksonville, supported by a more efficient operating structure.”
David Phipps, Chief Executive Officer and President of NextPlat Corp
Crescent Private Credit Income Corp reported total investment income of $62.2 million for the nine months ended September 30, 2026, a significant increase from $30.8 million in the prior year period. Net investment income rose to $33.2 million, though the company recorded net realized and unrealized losses on investments during the period.
Seritage Growth Properties continued its strategic plan to liquidate its real estate portfolio, focusing on asset dispositions to retire outstanding debt. The filing reflects a decrease in rental income as properties are sold, consistent with the company's transition toward dissolution.
Farmers & Merchants Bancshares, Inc. reported net income of $5.75 million for the nine months ended September 30, 2026, an increase from $4.07 million in the prior year period. The company saw a significant rise in net interest income to $20.7 million, driven by higher loan yields and a decrease in interest expense on deposits.
Biofrontera Inc. reported a net loss of $11.8 million for the nine months ended September 30, 2026, an improvement from the $16.2 million loss in the prior year period. Product revenues grew significantly to $31.2 million compared to $24.6 million in 2025, while the company's cash position decreased to $3.2 million as of the reporting date.
For the nine months ended September 30, 2026, KKR Infrastructure Conglomerate LLC reported a net increase in net assets resulting from operations of $558.0 million, driven by $589.2 million in unrealized appreciation on investments. Total assets grew to $9.22 billion from $6.59 billion at year-end 2025, reflecting significant capital deployment and investment performance.